Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Lowered to $41.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its price objective lowered by Piper Sandler from $45.00 to $41.00 in a research note released on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy […]
More Stories
Landstar System, Inc. (NASDAQ:LSTR) Shares Acquired by Ameriprise Financial Inc.
Ameriprise Financial Inc. grew its stake in Landstar System, Inc. (NASDAQ:LSTR – Free Report) by 120.7% during the fourth quarter,...
Algert Global LLC Sells 101,687 Shares of Holley Inc. (NYSE:HLLY)
Algert Global LLC decreased its position in shares of Holley Inc. (NYSE:HLLY – Free Report) by 85.3% during the fourth...
BNP Paribas Financial Markets Has $5.37 Million Stock Position in Flex Ltd. (NASDAQ:FLEX)
BNP Paribas Financial Markets trimmed its position in Flex Ltd. (NASDAQ:FLEX – Free Report) by 71.7% in the fourth quarter,...
Ameriprise Financial Inc. Reduces Position in Exelon Co. (NASDAQ:EXC)
Ameriprise Financial Inc. reduced its position in shares of Exelon Co. (NASDAQ:EXC – Free Report) by 12.2% in the 4th...
United Parks & Resorts Inc. (NYSE:PRKS) Shares Bought by Bank of America Corp DE
Bank of America Corp DE lifted its stake in United Parks & Resorts Inc. (NYSE:PRKS – Free Report) by 40.8%...
Bank of America Corp DE Lowers Position in Universal Health Services, Inc. (NYSE:UHS)
Bank of America Corp DE decreased its position in shares of Universal Health Services, Inc. (NYSE:UHS – Free Report) by...